PLU
MRVI icon

Performa Ltd (US)’s Maravai LifeSciences MRVI Stock Holding History

Performa Ltd (US)’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.78K Sell
2,750
-564
-17% -$1.91K ﹤0.01% 34
2025
Q4 		$10.8K Sell
3,314
-13,336
-80% -$44.9K ﹤0.01% 26
2025
Q3 		$47.8K Sell
16,650
-6,340
-28% -$16.2K 0.01% 18
2025
Q2 		$55.4K Buy
22,990
+5,740
+33% +$12.1K 0.02% 19
2025
Q1 		$38.1K Buy
17,250
+12,250
+245% +$48.4K 0.01% 20
2024
Q4 		$27.3K Buy
5,000
+4,300
+614% +$27.7K 0.01% 23
2024
Q3 		$5.82K Buy
700
+450
+180% +$3.89K ﹤0.01% 34
2024
Q2 		$1.79K Sell
250
-6,500
-96% -$56.1K ﹤0.01% 47
2024
Q1 		$58.5K Buy
6,750
+750
+13% +$5.07K 0.03% 21
2023
Q4 		$39.3K Buy
6,000
+3,175
+112% +$20.5K 0.02% 23
2023
Q3 		$28.3K Buy
2,825
+825
+41% +$9.06K 0.01% 24
2023
Q2 		$24.9K Buy
2,000
+200
+11% +$2.7K 0.01% 26
2023
Q1 		$25.2K Buy
1,800
+300
+20% +$4.31K 0.01% 26
2022
Q4 		$21.5K Buy
1,500
+1,250
+500% +$19.7K 0.01% 29
2022
Q3 		$6K Buy
250
+200
+400% +$5.02K ﹤0.01% 45
2022
Q2 		$1K Buy
+50
New +$1.58K ﹤0.01% 63

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Performa Ltd (US)'s MRVI Position: Q1 2026 in Review

Performa Ltd (US) reduced its Maravai LifeSciences (MRVI) stake by 17% in Q1 2026, selling an estimated $1.91K and leaving 2,750 shares worth $7.78K. The position accounts for ﹤0.01% of the portfolio, ranked #34.

Performa Ltd (US) first reported a position in MRVI in Q2 2022 and has held it in 16 quarters since. The position peaked at $58.5K in Q1 2024. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Performa Ltd (US) held 2,750 shares of Maravai LifeSciences worth $7.78K as of Q1 2026.
  • Performa Ltd (US) sold 564 Maravai LifeSciences shares in Q1 2026, an estimated $1.91K.
  • Maravai LifeSciences made up ﹤0.01% of Performa Ltd (US)'s portfolio in Q1 2026, its #34 holding.
  • Performa Ltd (US) first reported a position in Maravai LifeSciences in Q2 2022 and has held it in 16 quarters since.
  • Performa Ltd (US)'s Maravai LifeSciences position peaked at $58.5K in Q1 2024.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Performa Ltd (US)'s 13F filing for Q1 2026, filed 6 May 2026.